These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19153360)

  • 21. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
    Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Possible zoledronic acid-induced dermatomyositis.
    Apalla Z; Tzellos T; Lallas A; Sotiriou E; Lefaki I
    Clin Exp Dermatol; 2012 Apr; 37(3):309-11. PubMed ID: 22007911
    [No Abstract]   [Full Text] [Related]  

  • 23. Hypocalcemic choreoathetosis and tetany after bisphosphonate treatment.
    Topakian R; Stieglbauer K; Rotaru J; Haring HP; Aichner FT; Pichler R
    Mov Disord; 2006 Nov; 21(11):2026-7. PubMed ID: 16972252
    [No Abstract]   [Full Text] [Related]  

  • 24. Annual zoledronic acid for osteoporosis.
    BMJ Group
    Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Metabolic bone diseases: benefits and risks of the treatment].
    Rizzoli R
    Rev Med Suisse; 2009 Jun; 5(207):1299-300. PubMed ID: 19626928
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid.
    Chennuru S; Koduri J; Baumann MA
    Intern Med J; 2008 Aug; 38(8):635-7. PubMed ID: 18284458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature.
    Kreutle V; Blum C; Meier C; Past M; Müller B; Schütz P; Borm K
    Swiss Med Wkly; 2014; 144():w13979. PubMed ID: 24964073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypocalcemia Secondary to Zoledronate Therapy in a Patient With Low Vitamin D Level.
    Epperla N; Pathak R
    WMJ; 2015 Aug; 114(4):163-6; quiz 167. PubMed ID: 26436186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach.
    Tirelli G; Biasotto M; Chiandussi S; Dore F; De Nardi E; Di Lenarda R
    Head Neck; 2009 Sep; 31(9):1249-54. PubMed ID: 19260132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
    Polyzos SA; Anastasilakis AD; Litsas I; Efstathiadou Z; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
    J Bone Miner Metab; 2010 Nov; 28(6):706-12. PubMed ID: 20533067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor.
    Hanamura M; Iwamoto T; Soga N; Sugimura Y; Okuda M
    Biol Pharm Bull; 2010; 33(4):721-4. PubMed ID: 20410614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates.
    Grasko JM; Herrmann RP; Vasikaran SD
    J Oral Maxillofac Surg; 2009 Mar; 67(3):645-9. PubMed ID: 19231794
    [No Abstract]   [Full Text] [Related]  

  • 33. Severe hypocalcaemia after being given intravenous bisphosphonate.
    Peter R; Mishra V; Fraser WD
    BMJ; 2004 Feb; 328(7435):335-6. PubMed ID: 14764499
    [No Abstract]   [Full Text] [Related]  

  • 34. By the way, doctor. Should I take an intravenous drug for osteoporosis?
    Robb-Nicholson C
    Harv Womens Health Watch; 2007 Jul; 14(11):8. PubMed ID: 17665505
    [No Abstract]   [Full Text] [Related]  

  • 35. [Acute anterior uveitis associated with the use zoledronic acid].
    Cavallasca JA; Reyt C
    Medicina (B Aires); 2014; 74(5):428-9. PubMed ID: 25347912
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety of bisphosphonates in the treatment of osteoporosis.
    Recker RR; Lewiecki EM; Miller PD; Reiffel J
    Am J Med; 2009 Feb; 122(2 Suppl):S22-32. PubMed ID: 19187809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zoledronic acid infusion and orbital inflammatory disease.
    Sharma NS; Ooi JL; Masselos K; Hooper MJ; Francis IC
    N Engl J Med; 2008 Sep; 359(13):1410-1. PubMed ID: 18815406
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug-induced dermatomyositis after zoledronic acid.
    Tong PL; Yu LL; Chan JJ
    Australas J Dermatol; 2012 Nov; 53(4):e73-5. PubMed ID: 23157790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consultation corner. Bone loss drug gives users a break.
    Bellantoni M
    Johns Hopkins Med Lett Health After 50; 2007 Dec; 19(10):6. PubMed ID: 18225340
    [No Abstract]   [Full Text] [Related]  

  • 40. Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma.
    Singh D; Khaira NS; Sekhon JS
    Ann Oncol; 2004 Dec; 15(12):1848. PubMed ID: 15550594
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.